 |
Jun Bao, PhD, MBA Dr. Jun Bao is Senior Vice President and Chief Business Officer. He has over 20 years of combined business and science experiences. Before he joined Shenogen, Jun was Director, Worldwide Business Development, Head of China at GlaxoSmithKline (GSK). Prior to GSK, he worked at Onyx Pharmaceuticals, ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities. Jun also worked as a finance manager in Procter & Gamble based in Cincinnati. Jun received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. He completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He has authored/co-authored more than 30 research publications and co-founded two start-up biotech companies. |
 |
Xue Bin
|
 |
Leon Chen Dr. Chen is Founder and Managing Partner of Frontline BioVentures. He has over eighteen years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1,000 Talent Project, and an adviser to BioBAY of Suzhou Industry Park. As a venture capital investor, his current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). During his 18 year pharma career, Dr. Chen also had several leadership positions at Roche Nutley in New Jersey, including Head of high throughput chemistry and project leadership in metabolic diseases and cancer. He is a co-inventor of two Roche drugs that have completed Phase II clinical trials in Asthma and in MED. He also served as a member at Roche’s Patent Coordination Committee at Nutley. Dr. Chen was the President of the Sino-American Pharmaceutical Professionals Association (SAPA) in 2001, and is now a member of the SAPA Board of Directors. |
 |
Li Chen, Ph.D. Dr. Li Chen is the co-founder and CEO of a newly established drug discovery and development company, Hua Medicine, which brings clinically differentiated medicine to the patients in China and rest of world. Before Dr. Chen founded Hua Medicine, he was the Chief Scientific Officer and Head of Research at Roche R&D Center (China) Ltd. and a member of Roche Pharma Research Leadership Team. As a founding Director in this position, Li was responsible for development and implementation of China drug discovery strategy, creation of China discovery portfolio, and management of China operation, including Biology, Chemistry, Pharmacology, Discovery Technology, Drug Supply and Drug Safety. Li received his Ph.D in Chemistry from Iowa State University. He was formerly a lecturer in Organic Chemistry at East China Normal University, and is currently an adjunct professor of Chemical Biology at Tongji University. He has over 70 publications in numerous peer-reviewed scientific journals and in patent literature. |
 |
Shaoyu Chen, Ph.D. Mr. Shaoyu Chen is a partner in the firm’s Food and Drug Practice Group, and the managing director of its China Food and Drug Practice, based in the firm’s Beijing and Shanghai offices. Mr. Chen has over a decade of experience in food and drug law, including serving in the government, and the biopharmaceutical and medical device industries Leveraging these hands-on government and industry experiences, Mr. Chen effectively assists multinational and Chinese pharmaceutical, biotechnology, medical device, food, and cosmetic companies and trade associations to address the most pressing regulatory law issues confronting business. Mr. Chen has the privilege to represent industry leaders such as Abbott, Amgen, AstraZeneca, BMS, Genentech, Gilead Sciences, Merck, Novartis, Stryker, Takeda, and UBC, as well as many start-up or mid-size firms on a full range of matters regulated by the U.S. FDA and China FDA (CFDA, formerly SFDA). |
 |
Samantha Du Samantha Du, Managing Director of Sequoia Capital China, focuses on healthcare investment. Prior to joining Sequoia in 2012, Dr. Du was the founder and CEO of Hutchison MediPharma Limited since 2001. She also co-founded Hutchison China MediTech Limited, where she acted as its CSO and played a key role in its sucessful IPO on UK Aim market. Before Hutchison MediPharma, Dr. Du worked at Pfizer US, where she was responsible foe global metabolic diseases licensing on the scientific side. Samantha started her industry career at Pfizer US global R&D headquarter, where she led teams involved in drug development in various stages and therapeutic areas, two of the products she worked on had received global regulatory approval and launch. Dr. Du received her Ph.D. in Biochemistry from University of Cincinnati. She is currently an adjunt professor at Fudan University and chairwoman of shanghai pudong drug innovation consortium. She is an recipient both of thousand talent program in shanghai and of shanghai Magnolia award. She is on the board of BGI tech, JHL biotech, Beta Pharma. |
 |
May-Kin Ho, PhD Dr. Ho is an advisory director to the firm. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. She joined Goldman Sachs in 1992 and was named managing director in 1998 and partner in 2002. Dr. Ho has been ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times. Prior to joining the firm, she held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company. Dr. Ho serves on the board of The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University and the Investment Committee of the Society for Neuroscience. She has also served on the Biological Chemistry Advisory Council at Harvard Medical School. Dr. Ho was a postdoctoral fellow at Harvard Medical School. She earned a PhD in Microbiology and Immunology from the State University of New York, Downstate Medical Center. |
 |
Kewen Jin Mr. Kewen Jin is a serial entrepreneur in China life science industry. He is currently Managing Director of Nimbus Innoworks, a life science incubator based in Suzhou. He was previously General Manager of Charles River Lab’s China company. Kewen has co-founded and served as CEO of several companies in CRO biotech and medical device. He is an advisor to Suzhou Biobay, a leading life science park in China. He served as advisor to several multinational pharmaceutical companies, investment and consulting firms and NGOs. He was a marketing and international operation executive with Wyeth from 1993 to 2000 , in the U.S. and in China. He was trained in medicine (Shanghai Jiaotong University), molecular biology (Rockefeller), and finance (Columbia). He was granted the 2005 Magnolia Award by the Shanghai government. He served as the founding Chair of the Shanghai CRO Association. He was a Board member for Bayhelix. |
 |
James Li Dr. James Li is the Vice President and General Manager, Amgen China where he is leading the company’s efforts in expanding business into the Chinese market and helping Chinese patients to access Amgen’s vital medicines. Prior to joining Amgen, Dr,. Li was a Partner at Kleiner Perkins Caufield & Byers’ life sciences practice, first in the US Pandemic Fund and later, in its China Fund. He successfully invested in a number of early stage and growth stage companies, and led a portfolio company that went to public in 2010. From 1991 to 2006, Dr. Li spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across the Asia Pacific Region when the Vaccine Division started operations in the region; he also successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s largest franchise in Asia. Dr. Li received his Medical Degree from Shanghai Medical University, followed by a Master of Science degree in Microbiology from the University of Montana. |
 |
Bo Liu, PhD Bo Liu, PhD, Principal, Venture Investments, joined Johnson & Johnson Development Corporation in January 2013. He is based in Shanghai, China. Most recently Dr. Liu was Director of Business Development and Strategic Planning with GlaxoSmithKline Consumer Healthcare China, where he led key strategic initiatives in mergers and acquisitions, licensing and portfolio optimization. Prior to joining GSK, he worked in the corporate development and strategy group with Charles River Laboratories in Boston, where he played an instrumental role in several strategic transactions. Dr. Liu has executed M&A and licensing transactions in the US, Europe and Asia (including China) with total considerations over $2 billion. Dr. Liu received a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago, and a Master of Medicine from the seven-year program of Tongji Medical University in Wuhan, China. He received residency training in Urology at Union Hospital of Tongji Medical University. |
 |
John Oyler John Oyler was the former Founder & CEO of BioDuro, a 700-person integrated research CRO in Beijing and former CEO of Galenea (Boston biotech started from MIT with funding from Otsuka). He was the former co-CEO of Genta (GNTA), a publically traded oncology company that subsequently grew in the late 1990s to $1.7B. He was also the former Founder and President of Telephia (bought by Nielsen). He received his MBA from Stanford, and his BS from the Massachusetts Institute of Technology. |
 |
Yinxiang Wang, Ph.D. Dr. Yinxiang Wang is the CEO and Chief Scientist of Zhejiang Beta Pharma, Inc. He is a member of the Chinese Program of Global Experts (also known as the “1000 Plan”).In his current position, Dr. Wang, is instrumental in the research and development of a great number of new drugs for oncology and diabetes. As the Chief Scientist and one of the main innovators at Zhejiang Beta Pharma, Dr. Wang headed the research team which developed and commercialized Icotinib Hydrochloride (Conmana®), a National Category 1 Novel Drug that is the first small molecule oncology drug specifically targeting cancer cells that is completely developed in China. Zhejiang Beta Pharma successfully obtained approval on Icotinib Hydrochloride from Center for Drug Evaluation at SFDA at the end of 2010 and started marketing Conmana® in 2011. Dr. Wang is also one of the founders of Zhejiang Beta Pharma New Drug Research Center in Beijing, established in 2003. Currently, he is leading the scientists at the center in researching and developing pipeline drugs that include eight Category 1 drugs and several Category 3 drugs, out of which five generic products have already been approved and commercialized. In 2011, Eli Lilly invested in and formed a strategic 27 alliance with Zhejiang Beta Pharma that marked the beginning of new collaboration efforts to develop future products and technologies. |
 |
Jerry Xiao Dr. Xiao received his Ph.D. in Pharmacology from The Second Military Medical University. While in his postdoctoral training at the University of Rochester, he founded a small pharmaceutical company in the U.S. Before joining FosunPharma in June 2008, he was an investment manager at a VC company. Currently, he is responsible for identifying, evaluating, and developing new product and technology opportunities from the whole globe, as well as directing FosunPharma Group’s investments to R&D companies. He has invested in two R&D companies and in-licensed three projects for FosunPharma. He is also a member of the Board of Directors of Fochon Pharma and Henlius Biotech |
 |
Steve Yang Dr. Steve Yang is Vice President, Head of R&D for Asia and Emerging Markets at AstraZeneca. He is based in Shanghai, China and is responsible for developing, implementing and aligning the company’s R&D strategy for Asia and Emerging Markets. Prior to joining AstraZeneca, Dr. Yang was Vice President, Head of Asia R&D at Pfizer, where he was charged with establishing and expanding the company’s research partnership network with academic institutions, biotechnology firms and Contract Research Organizations across Asia Pacific. He was also responsible for delivering a portfolio of preclinical and clinical stage projects targeting unmet medical needs of emerging markets. Prior to his leadership position in Asia, Dr. Yang was Executive Director and head of the company’s global R&D strategic management group. Before joining Pfizer Dr. Yang held a number of positions at IntraBiotics Pharmaceuticals, a US-based biotech company and also worked for Strategic Decisions Group (SDG), a management consulting firm for Fortune 100 companies. Dr. Yang is the co-founder of the BayHelix Group, a non-profit professional organization of Chinese life science business leaders. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, USA. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude in Biology from Michigan Technological University, USA. |
 |
Jimmy Zhang, PhD, MBA Dr. Jimmy Zhang is the Managing Director, MSD Early Investments – Greater China at Merck & Co. He's responsible for Merck's venture capital investments, licensing, acquisitions, external research collaboration, and alliance/partnership management in Greater China. Before joining Merck/MSD, Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage companies in drug discovery, vaccine, diagnostics, and healthcare IT. Jimmy is responsible for the business development and operations of Synergenics and some of its portfolio companies, and their businesses in China. Jimmy was previously a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis). Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with two Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition. Jimmy is a founding member and the current Chairman, Board of Directors of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, and a guest/adjunct professor at Tongji University, Shanghai. |
 |
Xun Zhu, MD |